Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
NCT04612894Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in thyroid cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04612894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612894.